If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!
CEF Control Peptides
Browse products name by alphabetical order:
The length of CEF (Cytomegalovirus, Epstein-Barr Virus, Influenza Virus) control peptide is 8 to 12 amino acids, and its sequence is derived from human cytomegalovirus, EB virus and influenza virus 1. These peptides are used to stimulate CD8+T cells to release IFN- γ. In the detection of many kinds of cytokines such as ELISPOT, they have important application value as positive control peptides. CEF peptides were first screened in 2002 based on their ability to recognize CD8+T cells. It comes from the antigenic epitope of the virus, so it has the antigenic property.
Structure of CEF peptide
CEF peptide is composed of 8 to 11 amino acids, and the sequence is as follows: GILGFVFTL (influenza A, HLA-A2), FMYSDFHFI (influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2).
CEF peptide can stimulate CD8+T cells to produce specific interferon-γ, which can be used as a positive control for the detection of γ-ELISA and F-Spot in human peripheral blood mononuclear cells (PBMCs). CEF control peptides are used as positive controls in ELISPOT tests to study specific immune responses to a variety of diseases, including infection, cancer, allergies and autoimmune diseases. In this case, the CEF peptide ensures that the cells in the study are active and visible. ELISPOT is also useful in developing vaccines, especially in HIV vaccines, where CEF peptides are also used as control.
1. Xu, Y., Li, H., Gao, R. L., Adeyemo, O., Itkin, M., & Kaplan, D. E. (2011). Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clinical Immunology, 139(3), 302-313.
2. Pohlmeyer, C. W., Laskey, S. B., Beck, S. E., Xu, D. C., Capoferri, A. A., Garliss, C. C., ... & Leffell, M. S. (2018). Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. PloS one, 13(2), e0192098.